ACER THERAPEUTICS INC. Proceeds from Common Stock Issued
ACER THERAPEUTICS INC. reported Proceeds from Common Stock Issued of $8.91 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-27.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfCommonStock · last filed 2023-03-27
- ACER THERAPEUTICS INC. proceeds from issuance of common stock for the quarter ending 2022-12-31 was $4.38M.
- ACER THERAPEUTICS INC. proceeds from issuance of common stock for the quarter ending 2022-09-30 was $1.00M.
- ACER THERAPEUTICS INC. proceeds from issuance of common stock for the quarter ending 2022-06-30 was $400.00K.
- ACER THERAPEUTICS INC. proceeds from issuance of common stock for the quarter ending 2022-03-31 was $3.12M, a 0.47% decline year-over-year.
- ACER THERAPEUTICS INC. proceeds from issuance of common stock for fiscal 2022 was $8.91M, a 183.84% increase from fiscal 2021.
- ACER THERAPEUTICS INC. proceeds from issuance of common stock for fiscal 2021 was $3.14M, a 69.10% decline from fiscal 2020.
- ACER THERAPEUTICS INC. proceeds from issuance of common stock for fiscal 2020 was $10.16M.
- ACER THERAPEUTICS INC. proceeds from issuance of common stock for fiscal 2017 was $21.51M.
| Period end | Proceeds from Issuance of Common Stock 0 month | Proceeds from Issuance of Common Stock 3 month | Proceeds from Issuance of Common Stock 6 month | Proceeds from Issuance of Common Stock 9 month | Proceeds from Issuance of Common Stock 12 month |
|---|---|---|---|---|---|
| 2022-12-31 | $4.38M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-27 | $5.39M derived: sum of 2 quarters · filed 2023-03-27 | $5.79M derived: sum of 3 quarters · filed 2023-03-27 | $8.91M 10-K · filed 2023-03-27 | |
| 2022-09-30 | $1.00M derived: 10-Q 9 month − 10-Q/A 6 month · filed 2022-11-14 | $1.40M derived: sum of 2 quarters · filed 2022-11-14 | $4.52M 10-Q · filed 2022-11-14 | $4.52M derived: sum of 4 quarters · filed 2023-03-27 | |
| 2022-06-30 | $400.00K 10-Q/A · filed 2022-11-14 | $3.52M 10-Q/A · filed 2022-11-14 | $3.52M derived: sum of 3 quarters · filed 2023-03-27 | $3.52M derived: sum of 4 quarters · filed 2023-03-27 | |
| 2022-03-31 | $3.12M derived: 10-K 12 month − 3 quarters · filed 2023-03-27 | $3.12M derived: sum of 2 quarters · filed 2023-03-27 | $3.12M derived: sum of 3 quarters · filed 2023-03-27 | $3.12M derived: sum of 4 quarters · filed 2023-03-27 | |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-27 | $0.00 derived: sum of 2 quarters · filed 2023-03-27 | $0.00 derived: sum of 3 quarters · filed 2023-03-27 | $3.14M 10-K · filed 2023-03-27 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q/A 6 month · filed 2022-11-14 | $0.00 derived: sum of 2 quarters · filed 2022-11-14 | $3.14M 10-Q · filed 2022-11-14 | $6.63M derived: sum of 4 quarters · filed 2022-11-14 | |
| 2021-06-30 | $0.00 derived: 10-Q/A 6 month − 10-Q 3 month · filed 2022-11-14 | $3.14M 10-Q/A · filed 2022-11-14 | $6.63M derived: sum of 3 quarters · filed 2022-11-14 | $11.36M derived: sum of 4 quarters · filed 2022-11-14 | |
| 2021-03-31 | $3.14M 10-Q · filed 2022-05-16 | $6.63M derived: sum of 2 quarters · filed 2022-05-16 | $11.36M derived: sum of 3 quarters · filed 2022-05-16 | ||
| 2020-12-31 | $3.49M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-02 | $8.22M derived: sum of 2 quarters · filed 2022-03-02 | $10.16M 10-K · filed 2022-03-02 | ||
| 2020-09-30 | $4.73M derived: 10-Q 9 month − 10-Q/A 6 month · filed 2021-11-19 | $6.67M 10-Q · filed 2021-11-19 | |||
| 2020-06-30 | $1.94M 10-Q/A · filed 2021-11-19 | ||||
| 2017-12-31 | $11.51M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-07 | $21.51M 10-K · filed 2018-03-07 | |||
| 2017-09-30 | $10.00M 10-Q · filed 2017-11-13 | ||||
| 2017-09-19 | $10.00M 10-K · filed 2019-03-07 | ||||
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-07 | $0.00 10-K · filed 2018-03-07 | |||
| 2016-09-30 | $0.00 10-Q · filed 2017-11-13 |